MODERATE TO SEVERE ECZEMA RESEARCH STUDY (56 WEEKS)

If you are aged 18 to 65 years old and have a clinical diagnosis of chronic eczema / atopic dermatitis (AD) for at least 1 year, you are invited to see if this research study is suitable for you.
Eligible participants must have moderate to severe eczema / atopic dermatitis (AD) affecting 10% or more of their body surface area (this equates to 10 palm prints). If you have a history of poor response to treatment with topical medications, or if your doctor has said topical treatments (such as creams) may not be right for you, or you have documented systemic treatment use for AD, this is also required.
Participants will have regular visits with an experienced research team and receive investigational IV infusion medication (active study drug) or placebo. There is no cost to participate, and participants will be reimbursed for study-related expenses. Participants will be asked to visit the study centre
about 23 times over a period of about 56 weeks.

For more detailed information about this clinical trial, please visit:
Study Details | NCT07235384 | A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis | ClinicalTrials.gov

Research staff contacts:
Principal Investigator
A/Prof Peter Foley

Sub Investigator
Dr Harmeet Bhullar
03 9623 9464
[email protected]

Sub Investigator
Dr Milan van Ammers
03 9623 9400
[email protected]

Lead Study Coordinator
Natasha Roney
03 9623 9435
[email protected]